Impact of Oncological Treatment on Human Reproduction
Authors:
M. Huser 1; L. Šmardová 2; P. Ventruba 1; J. Mayer 2
Authors‘ workplace:
Gynekologicko‑porodnická klinika LF MU a FN Brno
1; Interní hematoonkologická klinika LF MU a FN Brno
2
Published in:
Klin Onkol 2010; 23(3): 165-170
Category:
Reviews
Overview
Infertility is one of the most common permanent implications of oncology treatment of patients in reproductive age. The aim of this paper is to summarize current knowledge about the impact of basic modalities of oncology treatment on human reproduction. The authors describe the influence of chemotherapy, radiotherapy and pelvic surgery on the reproductive functions of men and women. Both chemotherapy and radiotherapy diminish the ovarian reserve of follicles, which is the main determining factor of premature ovarian failure. Modern markers of ovarian reserves are introduced, which in common clinical practice can effectively help to evaluate the risk of irreversible damage to the gonadal cells done by oncological disease or its curative treatment. If there is a good chance to permanently cure malignant disease in an oncological patient of fertile age, it is advisable to consider new modern techniques of reproductive protection in cooperation with reproductive medicine specialists.
Key words:
infertility – chemotherapy – radiotherapy – premature ovarian failure
Sources
1. Fridrichova M, Dienstbier Z, Loučka M et al. Výsledky sledování souboru pacientů léčených pro Hodgkinovu nemoc v létech 1971 až 1996. 2. část: Fertilita po terapii. Klin Onkol 2008; 21(3): 165– 168.
2. Crha I, Ventruba P, Zakova J et al. Survival and infertility treatment in male cancer patients after sperm banking. Fertil Steril 2009; 91: 2344– 2348.
3. Barr RD, Clark DA, Booth JD. Dyspermia in men with localized Hodgkin‘s disease. A potentially reversible, immune‑ mediated disorder. Med Hypotheses 1993; 40(3): 165– 168.
4. Spermon JR, Kiemeney LA, Meuleman EJ et al. Fertility in men with testicular germ cell tumors. Fertil Steril 2003; 79 (Suppl 3): 1543– 1549.
5. Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 1998; 27: 927– 943.
6. Wallace WH, Shalet SM, Hendry JH et al. Ovarian failure following abdominal irradiation in childhood: the radiosensitivity of the human oocyte. Brit J Radiol 1989; 62(743): 995– 998.
7. Bath LE, Critchley HO, Chambers SE et al. Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. Br J Obstet Gynaecol 1999; 106(12): 1265– 1272.
8. Chiarelli AM, Marrett LD, Darlington G. Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964– 1988 in Ontario, Canada. Am J Epidemiol 1999; 150(3): 245– 254.
9. Adam Z, Vorlíček J, Táborská E. Protinádorová chemoterapie. In: Adam Z, Vorlíček J, Koptíková J et al. Obecná onkologie a podpůrná léčba, 1. vyd. Praha: Grada 2003; 295– 354.
10. Schrader M, Heicappell R, Müller M et al. Impact of chemotherapy on male fertility. Onkologie 2001; 24(4): 326– 330.
11. Sanders JE, Hawley J, Levy W et al. Pregnancies following high‑dose cyclophosphamide with or without high‑dose busulfan or total‑ body irradiation and bone marrow transplantation. Blood 1996; 87: 3045– 3052.
12. Moore HC. Fertility and the impact of systemic therapy on hormonal status following treatment for breast cancer. Curr Oncol Rep 2000; 2(6): 587– 593.
13. Lower EE, Blau R, Gazder P et al. The risk of premature menopause induced by chemotherapy for early breast cancer. J Womens Health Gend Based Med 1999; 8: 949– 954.
14. Josting A, Rueffer U, Franklin J et al. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group. Blood 2000; 96(4): 1280– 1286.
15. Šmardová L, Král Z, Huser M et al. Damage to ovarian functions in young women treated with ABVD and BEACOPP chemotherapy for Hodgkin lymfoma. Annals of Oncology 2005; 16: 5.
16. Bokemeyer C, Schmoll HJ, van Rhee J et al. Long‑term gonadal toxicity after therapy for Hodgkin‘s and non‑Hodgkin‘s lymphoma. Ann Hematol 1994; 68(3): 105– 110.
17. Němec P, Huser M, Souček M. Možnosti ochrany reprodukčních funkcí u žen podstupujících léčbu cytotoxickými léky. Vnitř Lék 2008; 54(3): 191– 196.
18. Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio- chemotherapy for hemato‑ oncological neoplasias and other cancers. Leuk Lymph 1999; 33: 65– 76.
19. Bancsi LF, Broekmans FJ, Eijkemans MJ et al. Predictors of poor ovarian response in in vitro fertilization: a prospective study comparing basal markers of ovarian reserve. Fertil Steril 2002; 77(2): 328– 336.
20. van Rooij IA, Broekmans FJ, Scheffer GJ et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005; 83(4): 979– 987.
21. Sowers MR, Eyvazzadeh AD, McConnell D et al. Anti‑mullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrin Metab 2008; 93(9): 3478– 3483.
22. Meirow D, Levron J, Eldar‑ Geva T et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Eng J Med 2005; 353(3): 318– 321.
23. Hawkins MM. Pregnancy outcome and offspring after childhood cancer. BMJ 1994; 309(6961): 1034.
24. Grigg AP, McLachlan R, Zaja J et al. Reproductive status in long‑term bone marrow transplant survivors receiving busulfan‑ cyclophosphamide (120 mg/ kg). Bone Marrow Transplantat 2000; 26(10): 1089– 1095.
25. Green DM, Whitton JA, Stovall M et al. Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am J Obst Gynecol 2002; 187(4): 1070– 1080.
26. Marks DI, Friedman SH, Delli Carpini L et al. A prospective study of the effects of high‑dose chemotherapy and bone marrow transplantation on sexual function in the first year after transplant. Bone Marrow Transplant 1997; 19(8): 819– 822.
27. Vyskocil J, Poprach A, Petrakova K et al. Seminom v prvním klinickém stadiu – léčebné možnosti. Klin Onkol 2008; 21(3): 86– 92.
Labels
Paediatric clinical oncology Surgery Clinical oncologyArticle was published in
Clinical Oncology
2010 Issue 3
Most read in this issue
- Staging of Non‑ Hodgkin’s Lymphoma – Recommendations of the Czech Lymphoma Study Group
- The Current Role of Haematopoietic Stem Cell Transplantation in the Treatment of Lymphomas – Review
- Impact of Oncological Treatment on Human Reproduction
- What is the Clinically Appropriate Approach to a Terminally Ill Oncological Patient?